Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Spero Therapeutics (SPRO) Enterprise Value (2016 - 2025)

Spero Therapeutics' Enterprise Value history spans 10 years, with the latest figure at -$40.3 million for Q4 2025.

  • For Q4 2025, Enterprise Value rose 23.87% year-over-year to -$40.3 million; the TTM value through Dec 2025 reached -$40.3 million, up 23.87%, while the annual FY2025 figure was -$40.3 million, 23.87% up from the prior year.
  • Enterprise Value reached -$40.3 million in Q4 2025 per SPRO's latest filing, up from -$48.6 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$31.2 million in Q2 2025 to a low of -$146.4 million in Q4 2021.
  • Average Enterprise Value over 5 years is -$80.0 million, with a median of -$77.0 million recorded in 2023.
  • Peak YoY movement for Enterprise Value: soared 59.13% in 2022, then plummeted 85.99% in 2023.
  • A 5-year view of Enterprise Value shows it stood at -$146.4 million in 2021, then rose by 25.47% to -$109.1 million in 2022, then surged by 30.04% to -$76.3 million in 2023, then soared by 30.71% to -$52.9 million in 2024, then grew by 23.87% to -$40.3 million in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Enterprise Value are -$40.3 million (Q4 2025), -$48.6 million (Q3 2025), and -$31.2 million (Q2 2025).